Valuation
- Market cap
- 223,990,000
- Revenue TTM
- $52,740,000
- Net income TTM
- $-6,600,000
- PE ratio
- 11.74
- Forward PE
- 11.25
- Profit margin
- -12.51%
- Debt to equity
- 0.00
Trading
- Volume
- 1,198,800
- Avg volume
- 819,308
- Day's range
- $2.69 – $2.79
- Shares out
- 80,572,000
- Stochastic %K
- 84%
- Beta
- -0.09
- Analysts
- Strong Sell
- Price target
- $11.00
Company profile
Protalix BioTherapeutics, Inc., a biopharmaceutical company, engages in the development, production, and commercialization of recombinant therapeutic proteins based on the ProCellEx plant cell-based protein expression system. The company provides Elelyso for the treatment of Gaucher disease; and Elfabrio for the treatment of adult patients with a confirmed diagnosis of Fabry disease. It is also developing PRX-115, a...
Show more
Protalix BioTherapeutics, Inc., a biopharmaceutical company, engages in the development, production, and commercialization of recombinant therapeutic proteins based on the ProCellEx plant cell-based protein expression system. The company provides Elelyso for the treatment of Gaucher disease; and Elfabrio for the treatment of adult patients with a confirmed diagnosis of Fabry disease. It is also developing PRX-115, a plant cell expressed recombinant PEGylated Uricase, which is in Phase 2 trial for the treatment of gout; and PRX-119, a plant cell expressed PEGylated recombinant human DNase I product candidate for the treatment of neutrophil extracellular traps diseases. The company has agreements and partnerships with Pfizer; Fundação Oswaldo Cruz; and Chiesi Farmaceutici S.p.A. Protalix BioTherapeutics, Inc. has strategic partnership with Secarna Pharmaceuticals GmbH & Co KG. The company is headquartered in Hackensack, New Jersey.
- Industry
- Biotechnology
- Sector
- Healthcare
- Phone
- 201 696 9345
- Website
- https://www.protalix.com
- Address
- 2 University Plaza, Suite 100, Hackensack, United States
Latest news
No headlines yet.
